METTL4 and breast carcinoma: Gong et al. [39] suggested that ZC3H13 expressed less in breast cancer cell patients, and when METTL4 and ZC3H13 expressed particularly low, the prognosis tended to be unfavorable in four breast cancer subtypes through survival outcome analysis.